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Abstract
Summary A 5-year follow-up study was performed in
female RA patients with established disease looking at
vertebral fractures, scored on spinal X-rays, and non-
vertebral fractures. We found a high incidence rate of
vertebral and non-vertebral fractures in these patients
compared to population-based studies.
Introduction The aim of this study is to investigate the
incidence of vertebral and non-vertebral fractures over a 5-
year period in a cohort of postmenopausal patients with
established rheumatoid arthritis (RA).
Methods One hundred and fifty female patients with
established RA were included into the OSTRA cohort.
The cohort was assessed at baseline and at 5 years for
incident vertebral and non-vertebral fractures. Spinal X-rays
were taken at baseline and at follow-up and scored using
the semi-quantitative method according to Genant.
Results At 5 years, 102 patients (68%) were examined and
included in the present analysis. At baseline, the mean age
was 61 years, disease duration 17 years, body mass index
25.5 kg/m2 and 65% of the patients were rheumatoid factor
positive. Fifteen percent were treated with bisphosphonates,
25% received calcium supplementation and 20% vitamin-D
supplementation at baseline. During the 5-year follow-up, a
total of 16 patients out of 102 patients (16%) had a new
non-vertebral fracture [annual incidence of 3.2 (95% CI
1.8–5.5) per 100 patients/year]. In 18 patients out of 97
patients (19%), new vertebral fractures were identified on
spinal X-ray [annual incidence of 3.7 (95% C.I. 2.2–5.8)
per 100 patients/year].
Conclusions We found a high incidence of vertebral and
non-vertebral fractures in a cohort of women with estab-
lished RA compared to population-based studies.
Keywords Female . Fractures . Osteoporosis . Rheumatoid
arthritis . Vertebral fractures
Introduction
Osteoporosis is a well-known extra-articular feature of
rheumatoid arthritis (RA). Bone mineral density (BMD) is
decreased in patients with RA [1, 2]. The clinical endpoint
of osteoporosis, fractures are also more prevalent in RA
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patients compared to the general population [3–5]. Reasons
for this decreased BMD and increased prevalence of
fractures in RA include among others inflammation,
reduced physical activity and corticosteroid use [2]. Almost
all data regarding osteoporosis in RA are generated from
cross-sectional studies. Longitudinal studies are scarce,
especially studies with a focus on fractures. Recently, Van
Staa et al. reported that in a large case–control study, the
risk of fractures was about 1.5 times higher in RA patients
than in healthy controls [4]. In this study, only clinical
fractures were assessed and spinal X-rays were not
performed routinely to identify asymptomatic vertebral
fractures. However, these asymptomatic fractures are also
associated with an increased risk of new fractures and with
an increased morbidity [6, 7].
The OSTRA group (OSlo, TRuro, Amsterdam) is an
international collaboration investigating osteoporosis in
RA. Five years ago, the OSTRA group performed a study
in postmenopausal patients with RA and found that
radiological joint damage (total Larsen score) was associ-
ated with a low BMD and vertebral fractures [8].
To further clarify the association between RA and
osteoporosis, we performed a 5-year follow-up assessment
of this cohort. The main objective of this 5-year follow-up
study was to evaluate the incidence of vertebral and non-
vertebral fractures in female postmenopausal RA patients.
Patients and methods
Patients
All 150 patients from the original study were eligible to
participate in the follow-up study. The inclusion and exclusion
criteria for the baseline study have previously been described in
detail [8]. In short, in each of three centres, general
rheumatology clinics in Oslo (Norway), Truro (UK) and
Amsterdam (The Netherlands), 50 female patients were
consecutively enrolled. The patients included were 50–
70 years old and fulfilled the American College of Rheuma-
tology (formerly American Rheumatism Association) 1987
revised classification criteria for RA. The disease duration of
all patients was ≥5 years [9]. In total, 102 patients of the
original cohort consented to a follow-up assessment (33 from
Oslo, 34 from Truro and 35 from Amsterdam). The main
reasons for not participating in the follow-up study were as
follows: 15 moved away from the hospital area, five suffered
from severe co-morbidity, eight had died and 20 did not
participate for unknown reasons or could not be contacted.
The baseline characteristics of the 102 patients who had a
follow-up measurement did not differ from the characteristics
of all the 150 patients at baseline and of those patients (n=42)
that dropped out (lowest p=0.282; data not shown).
Demographics and medical history
Data at follow-up were collected from interviews,
clinical examination, questionnaires and patient’s medical
records and included height, weight, calcium intake,
history of falls (number of falls during the last year and
cause) and fractures (anatomical site and cause), current
and previous use of anti-osteoporotic [anti-resorptive
therapy (ART) and hormone replacement therapy
(HRT)] and disease-modifying anti-rheumatic drugs
(DMARDs), and history of corticosteroid use (previous
and current use, cumulative amount over the past 5 years,
use of 7.5 mg for >6 months and number of months on
corticosteroids). Physical disability was assessed by means
of the Health Assessment Questionnaire (HAQ; 20 items,
score range 0–3, with higher scores indicating worse
disability) [10].
Disease activity
Measures of RA disease activity were assessed with
visual analogue scales (0–100 mm) of pain and patient’s
global disease activity; 28 tender and swollen joint
counts, and acute phase reactants [the erythrocyte
sedimentation rate (ESR; mm/h) and C-reactive protein
(CRP; mg/L), both measured with standardised local
measurement techniques]. The modified 28 joints disease
activity score (DAS-28) was calculated according to
published guidelines [11]. Joint scores were performed by
experienced rheumatology nurses in Oslo and Truro and in
Amsterdam by a physician (MV). The mean ESR and CRP
were calculated based on all available measurements during
the 5-year follow-up.
Fractures
Non-vertebral Non-vertebral fractures and their cause were
assessed at 5-year follow-up by interview and were
validated by checking available data (radiology reports
and chart review). Low-energy traumatic fractures (i.e. a
fall from standing height) were regarded as osteoporotic
fractures.
Vertebral All spinal X-rays were taken according to local
protocol; the same protocol was used at baseline and follow-
up. Lateral radiographs of the spine were scored according to
the semi-quantitative method described by Genant et al. [12].
Scoring was performed individually by two trained observers
(MV and WL) and consensus both at baseline and follow-
up was obtained in cases of discrepancies between both
observers. Follow-up radiographs were scored blinded for
the baseline image, and the results were subsequently
compared to the baseline X-rays and scores to see if new
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vertebral fractures were detected. A fracture was scored as
an incident vertebral fracture if it was not present at
baseline or if there was a significant increase in loss of
height (more than 20%) in a vertebra which was already
fractures at baseline.
Ethics
The study protocol was approved by the local medical
ethical committees of the three centres and all patients gave
written informed consent.
Statistical analysis
Patients with incident fractures (vertebral or non-vertebral
fractures) were compared to those not having a new fracture
with regard to demographic variables, clinical variables and
BMD using two-sided t tests for continuous variables and chi-
square tests for counts. The incidence of patients with
fractures was expressed per 100 patients/year with 95%
confidence intervals (CI). Possible predictors of incident
vertebral and non-vertebral fractures were subsequently
examined in a multivariate logistic regression analysis. The
Baseline Follow-up
Age, years Mean (SD) 61 (6) na
Disease duration, years Median (range) 17 (6–25) na
IgM-RF positive (>25 U/ml) n (%) 67 (65) 67 (65)
Joint erosions present, patients n (%) 85 (83) 85 (83)
BMI, kg/m2 Mean (SD) 25.5 (5) 26.0 (5)
HAQ Mean (SD) 1.48 (0.62) 1.59 (0.89)
Corticosteroids
Ever use n (%) 65 (64) na
Use (during follow-up) n (%) na 58 (57)a
Months used (during follow-up) Mean (SD) na 43.8 (25.4)
≥7.5 mg for ≥6 months (during follow-up) n (%) na 18 (32)
Anti-osteoporosis medication
Anti-resorptive treatment n (%) 15 (15) 31 (31)b
Hormone replacement treatment n (%) 31 (30) 0 (0)b
Calcium supplementation n (%) 41 (40) 51 (50)b
Vitamin-D supplementation n (%) 28 (27) 43 (42)b
Vitamin-D and calcium supplementation n (%) 25 (24) 40 (39)
DMARD treatment (during follow-up)
Methotrexate n (%) na 66 (65)a
Duration, months Mean (SD) na 49.2 (21.7)
Sulfasalazine n (%) na 28 (27)a
Duration, months Mean (SD) na 40.3 (25.2)
TNF inhibitors n (%) na 20 (20)a
Duration, months Mean (SD) na 18.2 (11.3)
Other n (%) na 44 (43)a
Disease activity
DAS-28 Mean (SD) 5.4 (1.3) 3.6 (1.2)
ESR, mm/h Median (range) 27 (2–85) 18 (2–93)
CRP, mg/L Median (range) 11 (0–175) 5 (9–72)
Mean ESR, mm/h Mean (SD) na 20.9 (11.8)
Mean CRP, mg/L Mean (SD) na 12.6 (10.9)
Osteoporosis/osteopeniac
Osteoporosis (T-score<−2.5) n (%) 36 (35) na
Osteopenia (T-score<−1.5 and >−2.5) N (%) 26 (26) na
Fractures
Vertebral (Genant) n (%) 15 (25) 32 (33)
Non-vertebral n (%) 24 (24) 35 (35)
Table 1 Characteristics of the
102 patients with RA included
in the 5-year follow-up
na not applicable
a Used for at least 1 month during
the 5-year follow-up period
b Using at follow-up
c T-scores at either total hip and/or
vertebral spine
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criteria for entering independent variables in the logistic
regression analysis were a p value <0.2 in the univariate
analysis and a supposed clinical relevance for the dependent
variable. We were able to build a prediction model with only
significant covariates by using backward stepwise elimination
of the least significant covariate. All statistical analyses were
performed using SPSS (Chicago, IL, USA) version 15.0.
Results
Patient characteristics
The clinical characteristics of the 102 patients included in this
study are presented in Table 1. At baseline, the patients had a
mean (SD) age of 61 (6) years with a median (range) disease
duration of 17 (6–25) years, 83% of the patients had erosive
disease and 65% patients were rheumatoid factor positive.
The characteristics of the patients during follow-up are
shown in Table 1. During follow-up, 58 (57%) patients
used corticosteroids for a mean (SD) duration of 43.8
(25.4)months. ART was used by 15% of the patients at
baseline, and during follow-up an additional 16 patients
(16%) started with ART. Calcium and vitamin-D supple-
mentation were ever used by 50% and 42%, respectively,
for some time during the follow-up period. HRT was used
by 31 (30%) patients at baseline, but was discontinued by
all patients by the end of the study.
Incident non-vertebral fractures
A total of 18 patients reported 22 fractures. Two patients had
fractures due to high-energy trauma (traffic and skiing
accident). Thus, 16 (16%) patients had 17 osteoporotic
fractures. Fractures were reported at the following anatomical
sites: upper arm (n=3), wrist (n=4), hip (n=3), upper leg (n=
2), ankle (n=2), ribs (n=2) and pubic bone (n=1). The
annual incidence of patients with non-vertebral fractures in
our study was 3.2 (95% CI 1.8–5.5) per 100 patients/year.
Incident vertebral fractures
A total of 97 patients had lateral spine X-rays available for
evaluation. In a total of 18 (19%) patients, 22 new vertebral
fractures were identified. All incident fractures occurred in
vertebrae which were normal at baseline. Three patients
suffered more than one fracture. Most fractures as expected
were identified in the mid-thoracic and thoraco-lumbar
regions (Fig. 1). Fifteen of the 18 patients (83%) had at
least a new grade 2 vertebral fracture. The annual incidence
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Fig. 1 Distribution of new vertebral fractures
Table 2 Demographics and disease variables for patients with and without new vertebral and non-vertebral fractures baseline or follow-up
Vertebral fracture Non-vertebral fracture
Yes (18) No (79) p Yes (16) No (86) p
Age, years Mean (SD) 61 (6.5) 60 (5.8) 0.49 62 (5.0) 60 (6.1) 0.20
Disease duration, years Mean (SD) 17 (8.7) 17 (10.5) 0.95 18 (8.7) 17 (10.7) 0.70
IgM-RF positive N (%) 9 (50) 24 (30) 0.278 10 (62) 57 (67) 0.77
BMI, kg/m2 Mean (SD) 25.1 (3.8) 25.1 (4.0) 0.96 24.7 (2.9) 25.6 (5.1) 0.27
HAQ Mean (SD) 1.56 (0.35) 1.4 (0.72) 0.30 1.4 (0.75) 1.5 (0.68) 0.79
Use of corticosteroids N (%) 14 (78) 43 (54) 0.04 11 (69) 47 (54) 0.30
Use of ART during follow-up N (%) 7 (39) 24 (30) 0.49 10 (62) 21 (24) 0.002
BMD spine, g/cm2 at baseline Mean (SD) 0.981 (0.193) 1.159 (0.516) 0.12 0.969 (0.132) 1.151 (0.585) 0.08
BMD hip, g/cm2 at baseline Mean (SD) 0.843 (0.138) 0.840 (0.165) 0.96 0.751 (0.108) 0.858 (0.159) 0.003
DAS-28 at baseline Mean (SD) 5.2 (0.7) 4.7 (1.2) 0.06 4.8 (1.2) 4.8 (1.2) 0.89
Mean ESR, mm/h Mean (SD) 22.3 (13.3) 20.1 (11.5) 0.49 21.7 (13.6) 20.8 (11.6) 0.80
Mean CRP, mg/L Mean (SD) 15.7 (8.0) 11.3 (8.1) 0.07 12.5 (6.4) 12.7 (11.7) 0.82
Vertebral fracture at baseline N (%) 1 (5) 11 (15) 0.067 5 (31) 19 (22) 0.44
Non-vertebral fracture at baseline N (%) 8 (44) 15 (19) 0.02 4 (25) 10 (11) 0.12
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rate for a new morphometric vertebral fracture was 3.7
(95% CI 2.2–5.8) per 100 patients/year.
In total, 32 (32%) patients had either a new vertebral or a
new non-vertebral fracture.
Differences in patients with and without vertebral
and non-vertebral fractures
On average, patients with a new non-vertebral fracture had
a lower BMD at baseline compared to patients without a
new non-vertebral fracture. This was significant only for
the baseline BMD at the hip (p<0.05). In the group of
patients with a new non-vertebral fracture, more patients
used ART than in the group without a new non-vertebral
fracture (62% versus 24%, p<0.05).
When comparing patients with and without incident
vertebral fractures, there were significantly more patients
using corticosteroids (78% versus 54%) in the patients with a
new vertebral fracture during follow-up (p<0.05). Patients
with new vertebral fractures had also suffered significantly
more non-vertebral fractures at baseline (p<0.05), but
seemed to have less vertebral fractures at baseline
(p=0.067). There was also a trend for a higher disease activity
(mean CRP during follow-up and DAS-28 at baseline) in the
patients with a new vertebral fracture compared to patients
without a new vertebral fracture (Table 2).
Of the patients who were osteopenic at baseline, seven
(19%) sustained a new vertebral fracture and six (17%) a new
non-vertebral fracture during follow-up. In the group of
osteoporosis patients, there were seven (27%) new vertebral
and seven (27%) new non-vertebral fractures during follow-up.
Possible risk factors for incident fractures
In the multivariate logistic analysis, we identified BMD at
the total hip as an independent predictor for incident non-
vertebral fractures. BMD of the spine, ever steroid use,
vertebral fractures and non-vertebral fractures at baseline
were entered into the model, but were eliminated as not
significant (Table 3). Non-vertebral fractures at baseline
were an independent predictor of new vertebral fractures.
BMD of the spine, mean CRP over the follow-up period,
DAS-28 at baseline and ever steroid use were entered into
the model but were eliminated (Table 3). All regression
models were corrected for centre.
Discussion
In this 5-year follow-up study of postmenopausal women
with established RA, we found a high incidence of vertebral
and non-vertebral fractures. Baseline non-vertebral frac-
tures were an independent predictor of new vertebral
fractures and new non-vertebral fractures were indepen-
dently predicted by baseline BMD at the hip. This is the
first study to study incident non-vertebral fractures and
morphometric vertebral fractures in RA in a single study.
These data are also unique because of the duration of
follow-up (5 years).
In total, 19% of the patients had a new vertebral
fracture during the 5-year follow-up, corresponding to an
annual incidence of 3.7/100 patients/year. Because this is
an observational study, we have no data from a control
group to compare this annual incidence. Comparison
with other historical cohorts is possible. In the European
Prospective Osteoporosis Study (EPOS), a study of
fractures in the general population of 50 years and older,
the annual incidence rate of morphometric vertebral
fractures in females was 1.07 per 100 patient years
[13]. Mean age (63 years) for these patients is comparable
to our study. In another study by Nevitt et al., the annual
incidence of morphometric fractures was 0.8/100 patient
years. This study assessed fractures in subjects 65 years
and older from the general population [14]. Although
comparisons between studies should be considered with
caution, these studies give a clear indication of the high
incidence rate of vertebral fractures in our study. The
vertebral fractures we found were also predominantly
moderate and severe fractures (grades II and III). There are
two studies which performed a longitudinal study on
radiological detected vertebral fractures. Ørstavik et al.
found 6.7 incident deformities per 100 patient years in a
group of 255 female RA patients (mean age 54.3 years)
during a mean follow-up of 2.3 years [15]. This study,
however, did not use vertebral spine X-rays but morpho-
metric X-ray absorptiometry; this different technique may
B OR (95% CI) p value
Non-vertebral fractures
BMD total hip (1.0 g/cm2) −5.6 0.003 (0.001–0.42) 0.019
Constant 2.8 16.1 0.133
Vertebral fractures
Non-vertebral fracture at baseline 1.21 3.4 (1.3–9.6) 0.029
Constant 0.6 1.8 0.54
Table 3 Multivariate analyses
of incident fractures
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explain the higher incidence rate of vertebral fractures in
this otherwise comparable study. In the other study,
Katsumitsu et al. [16] found new vertebral fractures in
19 (16%) patients out 112 patients followed for 4 years.
This percentage is comparable to the percentage of
vertebral fractures found in our study during 5 years
(19%). Unfortunately, no data are given on the mean
disease duration and mean age of the included RA
patients.
In our study, we also found a high frequency of non-
vertebral fractures. When comparing our annual incidence of
3.1 per 100 patients/year with the incidence from the female
population in the EPOS study (1.9/100 patient years), it is
considerably higher. The EPOS is a study investigating limb
fractures in men and women aged 50 to 79 years [17]. Finigan
et al. also found an incidence 1.9 of new vertebral fractures
per 100 patient years in a 10-year follow-up population-
based study. Three hundred and sixty-seven female patients
were included into this study with an age (64.6 years) at
baseline which is comparable to our cohort [18]. Few studies
have investigated the incidence of clinical fractures in RA
patients. In a large database study by van Staa et al., they
identified an increased risk of fractures of 1.5 for all fractures
in RA patients compared to healthy controls [4]. This study
included all clinical fractures, also including clinical verte-
bral fractures. Nampei et al. found in a cohort of 209 RA
patients (86% female, mean age 60 years) an incidence of
patients with new fractures of 11.5/100 patient years [19].
This is a very high incidence, but this study investigated all
patients with pain suspicious of a fracture very thoroughly
(including MRI) for fractures, which could very well explain
the high incidence of fractures in this study.
In our study, we found few risk factors for new fractures.
Our study only revealed well-known risk factors for new
vertebral fractures and new non-vertebral fractures, respec-
tively baseline non-vertebral fractures and BMD of the hip
at baseline. We did not find any specific RA-related factors
to be predictors for new fractures. Mean CRP and baseline
DAS-28 showed a trend to be increased in patients with a
new vertebral fracture (Table 3), but were not independent
predictors of future vertebral fractures.
Our study has several limitations. We performed meas-
urements at baseline and at follow-up at 5 years. This is a
quite long period and measurements like DAS-28 at
baseline and follow-up will probably not properly reflect
the fluctuation of the disease activity during that period.
This could explain why we found no associations between
fractures and disease activity. Another reason for not
finding an association could be that joint scores were
performed by different investigators, which can cause some
variability in measurements. However, we also did not find
an association with objective disease activity measures like
CRP and ESR. Finally, our studied population might also
be too small to find risk factors in rheumatoid arthritis for a
multifactorial disease like osteoporotic fractures. Another
limitation of having only measurements at baseline and
5 years is that we were not able to properly investigate the
relationship between timing of the use of anti-resorptive
treatment and new fractures especially vertebral fractures. It
could be very likely that bisphosphonates were started after a
fracture occurred and this is probably the reason is whywe did
not find a protective effect of bisphosphonates for example.
In conclusion, in our study we found a high incidence
rate of vertebral and non-vertebral fracture rates during a
follow-up of 5 years in patients with established RA
compared to the general population.
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